Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of a new concentration of a fixed-dose combination drug called EF190 in women with moderate acne vulgaris. This Phase III randomized, double-blind, placebo-controlled, adaptive, multicenter study aims to compare the experimental drug with a placebo over six 28-day treatment cycles in female participants aged 14 to 45 years. The study addresses moderate acne characterized by specific lesion counts and includes participants who have had acne for at least six months. Participants will be randomly assigned in a 21 ratio to receive either the experimental drug, containing cyproterone acetate 2 mg and ethinyl estradiol 0.02 mg in a 24 active plus 4 inactive tablet regimen, or a matching placebo. Both groups will receive treatment for six consecutive 28-day cycles alongside standard skin care. The treatment starts on the 28th day after menstruation. In addition to study drug administration, a subgroup will undergo extra assessments including acne questionnaires, ovarian activity tests, photographic documentation, and special lab and ultrasound exams. Participants will attend five in-person visits screening, randomization, and three follow-ups occurring on day 15 of each treatment cycle. They will also receive three phone calls during cycles 2, 4, and 5 to support adherence, monitor side effects, and ensure contraceptive use. Researchers will measure reductions in inflammatory and total acne lesions and changes in acne severity through clinical assessments and questionnaires. The study includes safety monitoring and aims to complete participation within about 24 weeks.